BI
Bio Essence Corporation
BIOE · OTC
$0.18 +0.00% (+$0.00)
1M -4.26%
Market Cap $7.20M
P/E Ratio 4.75x
Div. Yield -
ROE -
Bulios Fair Price
$0.14
23.1% downside
Current Price
$0.18
Undervalued Fair Value Overvalued
According to Bulios Fair Price, BIOE is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
92 /100
Cheap EV/EBITDA 5.66x
P/S 2.47x
P/B 3.07x
Growth
100 /100
Growing Rev. growth 45.07%
FCF growth N/A
Book val. growth N/A
Profitability
100 /100
Strong Net margin 52.12%
Op. margin 52.86%
FCF margin 36.95%
Quality
92 /100
Excellent ROA 37.91%
Asset turnover 0.73x
ROIC 38.84%
Debt
72 /100
Low Current ratio 0.38x
Int. coverage 316.33x
Net debt/EBITDA 0.98x
Stability
3 /100
Unstable Rev. volatility 296.01%
EPS volatility 114.85%
Profitable years 1
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about BIOE
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Yin Yan
Employees
4
Headquarters
Irvine